AGE-RELATED MACULAR DEGENERATION (AMD) · White paper
Age-related Macular Degeneration (AMD) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About age-related macular degeneration (amd) — and why its trials are hard
Age-related macular degeneration damages the macula, the central retina responsible for sharp vision, and is the leading cause of irreversible blindness in older adults in developed countries. It divides into dry (atrophic) AMD, culminating in geographic atrophy, and wet (neovascular) AMD driven by choroidal neovascularization. Roughly 200 million people are affected worldwide, projected to near 300 million by 2040. Trials are challenging for several reasons. Disease progression is highly variable between patients, so studies need long follow-up and careful stratification by AMD stage. Diagnostic misclassification of stage introduces noise, and the historic endpoint, best-corrected visual acuity, changes slowly in dry AMD, forcing reliance on anatomical surrogates such as geographic-atrophy lesion growth on fundus autofluorescence and OCT, whose link to functional vision is debated. Wet-AMD trials must show non-inferiority to established anti-VEGF agents while proving extended dosing intervals. Recruitment, retention, adherence to frequent intravitreal injections, and consistent central image reading all critically affect data quality and FDA acceptability.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| faricimab (Vabysmo) | 2022 | neovascular (wet) AMD; also diabetic macular edema (dual Ang-2 and VEGF-A inhibitor) | TENAYA and LUCERNE | mean change in BCVA from baseline at ~year 1 (non-inferiority to aflibercept) | BCVA gains non-inferior to aflibercept (~+5.8 to +6.6 letters) with up to every-16-week dosing |
| aflibercept 8 mg (Eylea HD) | 2023 | neovascular (wet) AMD (higher-dose anti-VEGF) | PULSAR | mean change in BCVA at week 48 (non-inferiority to aflibercept 2 mg) | non-inferior visual-acuity gains with extended dosing intervals up to every 12-16 weeks |
| pegcetacoplan (Syfovre) | 2023 | geographic atrophy secondary to dry AMD (complement C3 inhibitor) | OAKS and DERBY | change in total GA lesion area on fundus autofluorescence over 12 months | reduced GA lesion growth vs sham (~18-22% with monthly dosing; no proven visual-function benefit) |
| avacincaptad pegol (Izervay) | 2023 | geographic atrophy secondary to dry AMD (complement C5 inhibitor) | GATHER1 and GATHER2 | rate of GA lesion growth over 12 months | reduced GA growth rate vs sham (~14-35% across trials); no direct visual-acuity benefit shown |
| ranibizumab-nuna (biosimilar) (Byooviz) | 2021 | neovascular (wet) AMD, macular edema, myopic CNV (first ranibizumab biosimilar) | biosimilarity study vs Lucentis | equivalence in BCVA change | clinical equivalence to reference ranibizumab (exact letter difference unverified) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in age-related macular degeneration (amd) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| pegpleranib (Fovista, anti-PDGF) — NCT01940900 (Phase 3 with anti-VEGF) | did not meet primary endpoint of mean BCVA change at month 12 when added to anti-VEGF | combination with ranibizumab provided no visual-acuity benefit over anti-VEGF alone, ending PDGF combination strategy for wet AMD |
| lampalizumab (anti-factor D) — NCT02247479 (SPECTRI/CHROMA) | failed to reduce geographic-atrophy progression vs sham | the complement factor-D target did not slow GA growth, showing that complement inhibition benefit is pathway- and agent-specific |
| abicipar pegol (anti-VEGF DARPin) — NCT02462928 (SEQUOIA/CEDAR) | met efficacy but rejected/withdrawn due to high intraocular inflammation | unacceptable rate of intraocular inflammation gave an unfavorable benefit-risk balance despite extended dosing |
Choosing the right endpoint
Primary endpoints that matter in age-related macular degeneration (amd) trials
- Best-corrected visual acuity (BCVA, ETDRS letters) — The gold-standard functional endpoint for wet AMD, but changes slowly and can be near-stable in early dry AMD, limiting sensitivity.
- Geographic-atrophy lesion area/growth — Primary anatomical endpoint for dry AMD via fundus autofluorescence and OCT; objective but its correlation with patients' functional vision is contested.
- Anatomical OCT measures (retinal fluid/thickness) — Sensitive to anti-VEGF activity and dosing intervals, useful as a structural surrogate in wet-AMD extended-dosing trials.
- Low-luminance visual acuity / microperimetry — Capture functional deficits (dim-light vision, retinal sensitivity) that standard BCVA misses, valuable for detecting subtle progression.
- Patient-reported outcomes (NEI-VFQ) — Quantify real-world impact on daily living, but subjective and must be paired with objective structural/functional measures.
How iNGENū runs age-related macular degeneration (amd) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Age-related Macular Degeneration (AMD) clinical trials — FAQs
Why is geographic atrophy so hard to treat and study?
What do newer wet-AMD drugs like faricimab and Eylea HD offer?
Why did drugs like abicipar and lampalizumab fail?
Ready to discuss your age-related macular degeneration (amd) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal